

Contents

Dedication	v
Preface	vii
List of Contributors	xiii
PART I. BASIC MECHANISMS OF IMMUNE EVASION	
1 HLA Class I Antigen-Processing Machinery and HLA Class I Antigen-Derived Peptide-Complex Defects in Tumor-Cell Escape	3
<i>Michael Campoli, Chien-Chung Chang, Xin-Hui Wang, and Soldano Ferrone</i>	
2 Immune Defects in T Cells From Cancer Patients: <i>Parallels in Infectious Diseases</i>	35
<i>Augusto C. Ochoa, Paulo C. Rodriguez, Jovanny Zabaleta, Pelayo Correa, and Arnold H. Zea</i>	
3 Malfunction of the Dendritic Cell System in Cancer	49
<i>Zoya R. Yurkovetsky, Irina L. Tourkova, Levent Balkir, Lori Perez, Galina V. Shurin, Gurkamal S. Chatta, and Michael R. Shurin</i>	
4 CD4+ T-Cell-Mediated Immunity to Cancer	67
<i>Tomohide Tatsumi, Amy Wesa, James H. Finke, Ronald M. Bukowski, and Walter J. Storkus</i>	
5 Immunological Ignorance in Cancer	87
<i>Koji Tamada and Lieping Chen</i>	
6 The Role of Receptor-Mediated Apoptosis in T-Cell Dysfunction	101
<i>Hannah Rabinowich and Brian R. Gastman</i>	
7 Alterations in T-Cell Signaling Pathways and Increased Sensitivity to Apoptosis	119
<i>Ithaar H. Derweesh, Luis Molto, Charles Tannenbaum, Patricia Rayman, Christina Moon, Cynthia Combs, Thomas Olencki, Paul Elson, Ronald M. Bukowski, and James H. Finke</i>	
8 The Role of Tumor Gangliosides in the Immune Dysfunction of Cancer ...	145
<i>Stephan Ladisch</i>	
9 Interleukin-10-Induced Immune Suppression in Cancer	157
<i>Arvin S. Yang and Edmund C. Lattime</i>	
10 Accentuating Tumor Immunity Through Costimulation: <i>A Detailed Analysis of OX40 Engagement and CTLA-4 Blockade</i>	173
<i>Andrew D. Weinberg, Dean E. Evans, and Arthur A. Hurwitz</i>	

11	Optimizing T-Cell Adoptive Immunotherapy to Overcome Tumor Evasion	195
	<i>Peter A. Cohen, Gregory E. Plautz, James H. Finke, and Suyu Shu</i>	
12	Tumor Resistance to Apoptosis: <i>Mechanisms of Evasion and Implications for Radiation and Chemotherapeutic Strategies</i>	215
	<i>Robert G. Uzzo, Paul Cairns, Nickolai Dulin, Eric M. Horwitz, Alan Pollack, and Vladimir Kolenko</i>	
PART II. CLINICAL RELEVANCE OF IMMUNE EVASION		
13	The Development and Reversal of T-Cell Tolerance in Cancer Patients Receiving Peptide-Based Vaccines	237
	<i>Ena Wang and Francesco M. Marincola</i>	
14	Altered Signaling in T Lymphocytes of Patients With Cancer: <i>A Biomarker of Prognosis?</i>	257
	<i>Theresa L. Whiteside</i>	
15	Allogeneic Hematopoietic Blood-Cell Transplantation as Immunotherapy for Metastatic Renal Cell Carcinoma	279
	<i>Richard W. Childs and Cristian A. Carvalho</i>	
16	Immune Defects in Patients Suffering From Non-Hodgkin's Lymphoma	295
	<i>Thomas Zander, Daniel Re, Michael von Bergwelt-Baildon, Jürgen Wolf, and Joachim L. Schultze</i>	
17	Immune Dysfunction in Classical Hodgkin's Lymphoma	315
	<i>Arjan Diepstra, Ewerton M. Maggio, Anke van den Berg, and Sibrand Poppema</i>	
18	Lung Cancer and Immune Dysfunction	335
	<i>Steven M. Dubinett, Sherven Sharma, Min Huang, Jenny T. Mao, and Raj K. Batra</i>	
19	Primary Malignant Brain Tumors: <i>Immune Defects and Immune Evasion</i>	351
	<i>Lucinda H. Elliott, Lorri A. Morford, William H. Brooks, and Thomas L. Roszmam</i>	
	Index	373



<http://www.springer.com/978-1-58829-183-7>

Cancer Immunotherapy at the Crossroads
How Tumors Evade Immunity and What Can Be Done
Finke, J.H.; Bukowski, R.M. (Eds.)
2004, XVII, 386 p., Hardcover
ISBN: 978-1-58829-183-7
A product of Humana Press